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Abstract
Background: Cytoplasmic linker-associated protein 2 (CLASP2) belongs to a family of microtubule plus-end tracking
proteins that localizes to the distal ends of microtubules and regulate microtubule dynamics. We speculated that it
might be involved in the epithelial-mesenchymal transition (EMT) and progression of bladder cancer (BC).
Methods: Western blotting and RT-PCR were used to detect the changes at protein and mRNA levels in BC cell
lines. Cell proliferation, clonogenic formation, wound healing and chamber invasion assay were used to investigate
the abilities of cellular proliferation, migration and invasion. The data of BC patients treated with transurethral
resection of the bladder tumor (TURBT) was collected and analyzed. The levels of mRNA of CLASP2 and EMT-related
markers in tumor and urine samples were tested by RT-PCR.
Results: Expressions of CLASP2 varied in four BC cell lines. Manipulation of CLASP2 expression changed EMT-related
markers. CLASP2 could promote proliferation, migration and invasion in BC cell lines. The combination (CLASP2 +
E-cadherin mRNA in urine) could better discriminate the patients with or without 2-years progression compared
with tumor grade after TURBT.
Conclusion: CLASP2 is involved in the EMT and progression of bladder urothelial cancer. Simultaneous urine-based
detection of CLASP2 and E-cadherin mRNA can efficiently discriminate patients with or without 2-years progression
after TURBT.
Keywords: CLASP2 protein, Cell proliferation, Disease progression, Epithelial-mesenchymal transition, Urinary
bladder neoplasms
Background
Bladder cancer (BC) is the most common carcinoma of
the urinary tract. The cancer is the sixth leading cancer
in men and the tenth in women throughout the world
[1]. BC are classified as non-muscle-invasive bladder
cancer (non-MIBC) (pTa, pT1 or carcinoma in situ
[CIS]) or invasive cancer (pT2, pT3 or pT4) with the
latter carrying a worse prognosis [2, 3]. Most newly
diagnosed BC (75%) are non-MIBC (confined to the
bladder mucosa or to the lamina propria), which are
treated by transurethral resection of the bladder tumor
(TURBT) followed by intravesical instillation therapy [4].
With high rates of recurrence and progression to inva-
sive cancer, non-MIBC requires frequent follow-up and
repeated treatments. Consequently, the cost per non-
MIBC patient is the highest of all cancers [5]. Because of
the high risk of progression, discrimination and manage-
ment of non-MIBC cases with greater progressive poten-
tial to MIBC is demanding. Unfortunately, few tools with
very satisfactory efficacy can be used to predict early
progression in non-MIBC patients. Therefore, it is of
paramount importance to better understand the molecu-
lar mechanisms involved in the initiation and progression
of BC. Identification of novel biomarkers associated with
disease progression and metastasis of BC and combination
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of their application with traditional diagnostic and
prognostic parameters would contribute to develop-
ment of effective strategies for the prevention, early
diagnosis and treatment of BC.
Cytoplasmic linker-associated protein 2 (CLASP2)
belongs to a family of microtubule plus-end tracking
proteins that localizes to the distal ends of microtubules
and regulates microtubule dynamics. CLASP2 functions
in various microtubule-dependent processes, including
cell division, cytoskeletal remodeling for cell migration,
podosome regulation, and stabilization of adherens
junctions [6–9]. These studies suggested CLASP2 might
be implemented in cancer progression.
Epithelial-mesenchymal transition (EMT) has been
reported to be involved in the critical mechanism for the
acquisition of the invasive phenotype in various type of
tumor, including bladder cancer [10]. EMT has been
well characterized as a multistep process including
dissolution of local basement membrane, loss of the epi-
thelial polarity and tight junctions, switch of the adherens
junction subtypes, and cell migration [11]. On the other
hand, CLASP2 is central to coupling the organization of
intracellular vesicle transport to the remodeling of cell-
matrix interactions. In this process, CLASP2 promote the
stability of peripheral microtubules [12]. However it is not
known whether CLASP-mediated EMT and microtubule
stabilization is important for cell migration.
Previous study showed that CLASP2 interacts with
p120-catenin and governs microtubule dynamics at
adherens junctions. The levels of expression of CLASP2
affected the localization of the other protein to cell-cell
contacts and altered adherens junctions dynamics and
stability [6]. Moreover, CLASP2 interacts with CLIP,
binds to microtubules, and has microtubule-stabilizing
effects [13–15]. Cell migration involves a preferential
reduction in microtubule dynamics at the leading edge
relative to the trailing edge of cells. CLASP2 could play
an essential role in cytoskeletal polarization during
metastasis and invasion of cancer cells [16]. Thus we
speculated that CLASP2 might be involved in the EMT
and progression of bladder urothelial cancer. In the
present study, we first found CLASP2 could promote
EMT and BC progression in vitro. Furthermore, our
clinical data showed urine-based detection of CLASP2
and E-cadherin can predict early progression after
TURBT.
Methods
This study was approved by the ethical committee of
Xiangya hospital. All clinical investigations had been
conducted according to the principles expressed in the
Declaration of Helsinki. Written consent was obtained
from all the patients. Tumor of urine samples were
collected as part of routine care.
Cell lines and cell culture
The human bladder carcinoma cell lines CRL 1749, J82,
T24 and HTB 9 (purchased from American Type
Culture Collection, ATCC) were used in the present
study. The cells were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine
serum (FBS) in a humidified incubator with 5% CO2 at
37 °C.
Western blot analysis
For western blot assessment, the cells were plated in
culture dishes. Cells were harvested by scraping and
then washed with phosphate-buffered saline (PBS). Cells
were collected following centrifugation at 1,100 rpm and
pellets were resuspended in lysis solution. Protein was
electrophoresed using Bis-Tris gel (Invitrogen Life
Technologies, Carlsbad, CA, USA). The protein was
transferred to a nitrocellulose membrane (Invitrogen
Life Technologies). The primary antibody was added
to the culture with milk (2.5% w/v) and allowed to
incubate overnight at 4 °C. The membrane was then
washed prior to the addition of the appropriate horserad-
ish peroxidase-linked secondary antibody and incubation
for 1 h at room temperature. The primary antibodies
were anti-CLASP2, anti-E-cadherin, anti-vimentin
(Cell Signaling Technology, USA) and anti-GAPDH
(Santa Cruz Biotechnology, USA). The membrane was
then washed three times for 15 min each, prior to
the addition of SuperSignal Chemiluminescent sub-
strate (Pierce Biotechnology, Inc.) and then immedi-
ately visualized using a ChemiDoc Imaging system
(Bio-Rad).
Establishment of stable cell lines
The stably transduced bladder cancer cell lines aiming
to either increase or inhibit the expression CLASP2
were generated. ShRNA and cDNA transduction were
performed by Yinrunbio Inc, Changsha, China. Pre-mixed
Lentiviral Packaging System (Biosettia, SD, USA) was
utilized for viral packaging. CLASP2 expression was
down-regulated by infecting cells overnight with lenti-
viruses expressing a CLASP2-specific shRNA (Sigma-
Aldrich, USA). A non-targeting shRNA sequence was
used as control. The cDNA encoding the complete
coding region of CLASP2 cDNA was subcloned into
the lentiviral vector. The viral titre was adjusted for
optimal transduction levels in BC cells.
Cell proliferation assay
The cell growth rates were detected using a CCK-8 cell
proliferation assay (CCK-8 kit; Boster Ltd., Wuhan,
China) according to our previous reports [17]. In brief,
the cells (4 × 103/well) were seeded in a 96-well plate
and cultured at 37 °C in a 5% CO2 atmosphere. After
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incubation with CCK-8 solution (10 ml/well) for 1 h, the
absorbance value at 450 nm was measured using a micro
plate reader and analyzed at 24 h intervals, while the
650 nm served as the reference wavelength. All experi-
ments were performed in triplicate, and the results were
representative of three individual experiments.
Clonogenic formation assays
Clonogenic survival was defined as the ability of the cells
to maintain their clonogenic capacity and to form col-
onies. Briefly, 5000 cells were seeded into 12-well dishes
in 1 mL of medium. Medium was changed every 2 days
for 7–10 days to allow for colony formation. The cells
were fixed with 12.5% acetic acid in 30% methanol and
then stained with Brilliant Blue R. Each experiment was
performed in triplicate. Finally, positive colony forma-
tions were manually counted.
Wound healing assay
When the cells confluence reached about 70%, wounds
were created by a 1000-μl pipette tip. The cells were
then rinsed with medium to remove any free floating
cells and debris. Medium was then added, and culture
plates were incubated at 37 °C. Photographs were taken
immediately and after 24 h. The area of migrating cancer
cells was measured by Image J software. Duplicate wells
for each condition were examined, and each experiment
was repeated three times.
Cell invasive assay
Cell invasion was determined by using a modified two
chamber invasion assay with a pore size of 8 mm. For
migration assay, 2 × 105 HTB 9 and CRL1749 cells were
seeded in serum-free medium in the upper chamber.
After 12 h incubation at 37 °C, cells in the upper cham-
ber were carefully removed with a cotton swab and the
cells that had traversed the membrane were fixed in
methanol and stained with leucocrystal violet. The
number of invasive cells was determined by counting
the leucocrystal violet stained cells. For quantification,
cells were counted under a microscope in five fields (up,
down, median, left, right. ×200).
Real time semi-quantitative (RT-PCR)
Total RNA of urinary cell pellets was extracted using the
RNeasy Mini Kit (Qiagen, USA). The High-Capacity
cDNA archive kit (Applied Biosystems, USA) was used
to synthesize complementary DNA (cDNA). The cDNA
was synthesized on a PTC-200 Peltier Thermal Cycler
DNA Engine (MJ Research Inc., USA). The DNA Engine
Thermal Cycler with Chromo 4™ real-time detector
system and Opticon Monitor software (Bio-Rad Labora-
tories, USA) were used for real-time PCR analysis. Cycle
threshold (Ct) values were normalized to the house-
keeper GAPDH gene.
The specific primers were shown as following:
CLASP2 (forward: 5’- TTGTCGTCCTCTGTCAGTG




T -3’; reverse: 5’-TTGTCAACATCCTGTCTGAA-3’)
GAPDH (forward: 5’-ACCACAGTCCATGCCATCA
C-3’; reverss: 5’-TCCACCACCCTGTTGCTGTA-3’).
Patients and samples collection
Patients with newly diagnosed untreated bladder cancer
undergoing TURBT at our institution between April
2011 and May 2013 were retrospectively selected for
analysis. Radiological tests, including chest X-ray and
CT, were routinely done. The surgical methods were car-
ried out in accordance with the approved guidelines.
Specimens of bladder cancer were collected at Xiangya
hospital, and pathological examination of was performed
by experienced genitourinary pathologists. Tumor stage,
grade, size, and the number of tumors were recorded.
Pathologic staging was determined according to the 2002
TNM classification, and pathologic grading was deter-
mined according to the 1973 World Health Organization
classification (classified as G1, G2 and G3). Patients who
lacked muscle tissue or were found with invasive tumors in
TURBT specimen were excluded. Those patients who were
performed with repeated TURBT 2 – 6 weeks later after
the initial TURBT were not included in present study.
In all patients, cystoscopies were performed every
3 months for 2 years, then every 6 months for 5 years,
and annually thereafter. Disease progression was defined
as the development of Stage T1 or greater when the
initial diagnosis had been Tis or Ta or the development
of muscle-invasive BC (Stage T2 or greater) when the
initial diagnosis was Stage T1 [18].
All the patients received either an immediate intravesi-
cal instillation (pirarubicin, 30 mg) within 24 h of TURBT
or maintenance intravesical instillation for 1 year (piraru-
bicin, 30 mg, weekly for eight times and monthly for eight
times). None of these patients was treated with BCG,
because of its side effects and the government policy [19].
Total urine samples (100–150 mL) were collected
before TURBT. The urine was stored at 4 °C for up to
4 h and then centrifuged. The pellet was resuspended in
1 ml of TRIzol reagent and frozen at -80 C in liquid
nitrogen for further use.
Statistical analysis
We used 2-tailed χ2 tests to determine the significance
of differences between proportions. The Mann-Whitney
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U test or the Wilcoxon signed-rank test was used to
compare continuous variables. The clinical and molecular
markers likely to be associated with progression within 2
years (P <0.1) were selected to develop a prognostic
marker panel. The predictive significance was assessed by
univariable and multivariable logistic regression analysis.
The candidate variables (P <0.1 in the univariable model)
were included in the multivariable model for further
analysis. The value for predicting progression was evalu-
ated by calculating the area under the receiver operating
characteristic (ROC) curve. The ROC analysis was per-
formed using the DeLong test. [20] P values less than 0.05
were counted as significant. The statistical analysis was
performed using SPSS for Windows v.13.0 and Sigmaplot
for window 10.0.
Results
Expressions of CLASP2 varied in four BC cell lines
Four bladder cancer cell lines including J82, HTB 9,
CRL1749 and T24 were tested the expression of CLASP2
at protein level. CLASP2 were stronger expressed in
CRL1749 and T24 than J82 and HTB 9 cells (Fig. 1a).
Figure 1b showed representative examples of the morph-
ology of the non-manipulated four cell lines. HTB 9 and
CRL1749 were selected for further experiments.
Manipulation of CLASP2 expression changed EMT-related
markers
We arbitrarily enhanced CLASP2 expression in HTB 9
cells and depleted it in CRL1749 cells by transducing
lentiviral particles expressing CLASP2 cDNA or shRNA
respectively. As shown in Fig. 1c the expression of the
epithelial marker E-cadherin decreased significantly in
HTB 9 cells following overexpression of CLASP2,
whereas the expression of mesenchymal marker, vimen-
tin was upregulated. In contrast, E-cadherin expression
increased sharply in CRL1749 cells when expression of
CLASP2 was inhibited (Fig. 1c). Trend with vimentin
was opposite to that of E-cadherin.
CLASP2 was involved in proliferation and clonogenic
formation in BC cells
EMT was known to be related to cells proliferative
and clonogenic formation ability in cancers. Several
experiments were designed to investigate the asso-
ciation between CLASP2 and cell proliferative and
clonogenic formation ability after the involvement of
CLASP2 in EMT was confirmed. Cell proliferation
evaluated by CCK-8 assays showed that inhibited
expression of CLASP2 could decrease the cell prolif-
eration rate of CRL 1749 cells (Fig. 2a), whereas over-
expression of CLASP2 significantly promoted the
growth of HTB9 cells (Fig. 2b). Clonogenic formation
assay was performed to test the changes of cells
proliferative ability. As the assay suggest in Fig. 2c,
clonogenic formation of HTB 9 cells was promoted after
transduced with CLASP2 cDNA expressing vectors,
whereas impaired greatly in CRL1749 cells transduced
with CLASP2 shRNA vectors.
Fig. 1 Western blotting was used to test the expression level of CLASP2 in bladder cancer cell lines including J82, HTB 9, CRL1749 and T24 (a).
Nikon light microscope at a magnification of x200 was used to show the representative examples of the morphology of the non-manipulated cell
lines (b). HTB 9 and CRL1749 cells were transduced with lentiviral particles expressing CLASP2 cDNA or shRNA respectively. Western blotting was
used to detect the changes of expression of CLASP2 and EMT-related markers (c)
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CLASP2 could boost migration and invasion in BC cells
The effects of CLASP2 on cell migration and invasion
were determined with wound healing and transwell inva-
sion assay. HTB 9 cells with overexpression of CLASP2
were distinctively more migratory and invasive than
negative control cells (Fig. 3a-c). Knockdown of CLASP2
by shRNA inhibited these abilities in CRL1749 cells
(Fig. 3a-c). These results vividly demonstrated that
CLASP2 mediated the migration and invasiveness of BC
cells in vitro.
Taken together, these results suggested that over-
expression of CLASP2 could facilitate the growth and
aggressive phenotype of BC cells in vitro.
Patients and baseline characteristics
Totally 102 cases with superficial bladder cancers were
included. The baseline characteristics were showed in
Table 1. Of the 102 patients, 61 (59.8%) had recurrence.
Thirty-four (33.3%) had progression within 2 years after
initial TURBT. The median time to progression was
14 months (ranging from 8 – 22 months).
Twenty-nine (28.4%) patients received an immediate
intravesical instillation, and 73 (71.6%) patients received
maintenance intravesical instillation for 1 year. The
pathologic stage and grade distributions were as follows:
34 patients with Ta (33.3%) and 68 with pT1 (66.7%),
and 33 (32.4%) with G1, 49 (48%) with G2 and 20
(19.6%) with G3 (19.6%), respectively. There was no
significant difference between the patients with 2-years
progression and those without for tumor stage (P = 0.41),
whereas slight difference for tumor grade (P = 0.04). Only
three patients were found with concomitant carcinoma in
situ (CIS). Fifty-nine (57.8%) patients had smaller lesions
(<3 cm) and 43 (42.2%) larger tumors (>3 cm), and 44
(43.1%) patients had single lesions, whereas the remaining
58 (56.9%) presented had multiple tumors (P <0.05). RT-
PCR was used to test the mRNA levels of CLASP2 and
EMT-related markers (E-cadherin and Vimentin) in
bladder tumor and urines (Table 1). Significant differences
were shown in the levels of CLASP2 and E-cadherin
mRNA in the both tumor and urine between the patients
with and without 2-years progression (P <0.01). However,
only the mRNA level of Vimentin in the urine was found
with difference (P = 0.03), not in the tumor (P = 0.16).
Relationship between variables and progression with
2 years
Table 2 presented the results of univariable and multi-
variable logistic regression analysis for bladder cancer
progression within 2 years. According to the optimal
cut-off on the ROC curve, the levels of expression of
mRNAs were categorized into low and high expression.
Fig. 2 Evaluation of cell proliferation by CCK-8 assays showed that down-regulation of CLASP2 dramatically inhibited the cell proliferation rate of
CRL 1749 cells (a), whereas overexpression of CLASP2 significantly promoted the growth of HTB9 cells (b). Clonogenic formation assay found that
CLASP2 increased bladder cancer cells proliferation (c) (**P <.01, *P <0.05)
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Univariable analysis identified higher tumor grade,
higher mRNA levels of CLASP2 in the tumor and urine,
lower mRNA levels of E-cadherin in tumor and urine,
higher level of Vimentin mRNA in the urine as risk
factors for the progression within 2 years (P values seen
in Table 2). Tumor size and number did not show great
significance (P = 0.05 and P = 0.07), which were still
included in the multivariable analysis. In multivariable
analysis, tumor grade, CLASP2 and E-cadherin mRNA
levels in tumor and urine were associated with increased
risks of progression within 2 years (P values were listed
in Table 2).
To evaluate the prognostic potential, ROC curves were
generated for tumor grade, CLASP2, E-cadherin and
Vimentin mRNA levels in tumor and urine (Fig. 4 and
Table 3). Tumor grade were generally thought to be a
strong predictive factor for poor prognosis in cancers.
Area under curve (AUC) of ROC of tumor grade was
compared with those of CLASP2, E-cadherin and
Vimentin mRNA levels in tumor and urine. However,
the results showed that mRNA levels of individual
CLASP2 or other two EMT-related markers in tumor
and urine could not discriminate better than grade.
(P >0.05, Fig. 4 and Table 3). Table 3 indicated that the
prognostic potentials of mRNA levels of CLASP2 and E-
cadherin in urine were slightly greater than the others.
And because urine samples were easily attained, the
combined model (CLASP2 + E-cadherin mRNA in urine)
Fig. 3 Wound healing assay suggested that CLASP2 boosted migratory abilities in BC cells both under 70% (a) and 100% cells confluency (b).
Transwell invasion assay suggested that CLASP2 boosted invasive ability (c). The data are presented as the mean ± standard error of three
independent experiments (**P <0.01, *P <0.05)
Zhu et al. BMC Cancer  (2017) 17:105 Page 6 of 10
was evaluated. The results showed that the combination
could better discriminate the patients with or without
progression compared with tumor grade (P = 0.03)
(Fig. 4d).
Discussion
In present study, we confirmed that manipulation of
expression of CLASP2 could change the status of EMT
in bladder cancer cell lines in vitro. Moreover, we inves-
tigated the mRNA levels of CLASP2 and EMT-related
markers in both TURBT tumor samples and the corre-
sponding patients’ urine. And we found out that the
combination of mRNA levels of CLASP2 and E-cadherin










Total (%) 102 68 34
Gender
Male 72 52 20 0.11
Female 30 16 14
Age(years)
< 60 38 27 11 0.61
> 60 64 41 23
Intravesical instillation
Immediate 29 22 7 0.31
Maintenance 73 46 27
Tumor stage
Ta 34 25 9 0.41
T1 68 43 25
Tumor grade
G1 33 26 7 0.04
G2 49 33 16
G3 20 9 11
Concomitant CIS
Yes 3 1 2 0.26
No 99 67 32
Tumor size (cm)
< 3 59 44 15 0.07
> 3 43 24 19
Multiplicity
Single 44 34 10 0.06
Multiple 58 34 24
CLASP2 mRNA (tumor)
High 30 6 24 <0.01
Low 72 62 10
CLASP2 mRNA (urine)
High 55 24 31 < 0.01
Low 47 44 3
E-cadherin mRNA (tumor)
High 62 52 10 < 0.01
Low 40 16 24
E-cadherin mRNA (urine)
High 60 54 6 < 0.01
Low 42 14 28
Vimentin mRNA (tumor)
High 55 31 24 0.16
Low 47 37 10
Vimentin mRNA (urine)
High 62 36 26 0.03
Low 40 32 8
Table 2 Univariable and multivariable logistic regression analysis
Univariable analysis
RRa 95% CIb P
Gender (Male, Female) 1.12 0.91–1.22 0.67




Tumor stage (Ta, T1) 1.34 1.03–1.56 0.67
Tumor grade (G1 and G2, G3) 2.78 1.05–6.93 0.01
Concomitant CIS (No, Yes) 1.52 0.21–7.43 0.66
Tumor size (<3, >3 cm) 2.11 1.29–4.32 0.05
Multiplicity (Single, Multiple) 1.98 0.98–3.92 0.07
CLASP2 mRNA (low, high in tumor) 3.83 1.12–12.22 0.02
CLASP2 mRNA (low, high in urine) 2.71 1.09–7.77 < 0.01
E-cadherin mRNA (high, low in tumor) 2.97 1.17–9.82 0.04
E-cadherin mRNA (high, low in urine) 3.24 0.97–10.81 0.02
Vimentin mRNA (low, high in tumor) 1.24 0.78–2.87 0.32
Vimentin mRNA (low, high in urine) 1.19 0.26–4.98 0.09
Multivariable analysisc
RR 95% CI P
Tumor stage (Ta, T1) 1.14 0.91–1.86 0.78
Tumor grade (G1 and G2, G3) 2.19 1.01–4.98 0.04




Multiplicity (Single, Multiple) 2.32 1.18–4.22 0.18
CLASP2 mRNA (low, high in tumor) 2.76 1.02–10.11 < 0.01
CLASP2 mRNA (low, high in urine) 3.75 1.09–6.12 < 0.01
E-cadherin mRNA (high, low in tumor) 2.78 1.17–8.24 0.01
E-cadherin mRNA (high, low in urine) 3.34 1.12–7.45 0.01
Vimentin mRNA (low, high in tumor) 1.35 0.89–3.43 0.51
Vimentin mRNA (low, high in urine) 1.78 0.26–3.48 0.35
aRelative risk
bConfidence interval of the estimated RR
cMultivariable analysis adjusted for tumor grade, stage, size, multiplicity, levels
of CLASP2, E-cadherin and Vimentin mRNA in the tumor or urine
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in urine could be used as prognostic tools to predict the
progression within 2 years after TURBT for treating
patients with non-MIBC.
The significance of CLASP2 in EMT is not explicit,
especially in malignant disease. CLASP2 is closely associ-
ated with the function of microtubules which regulate
invasive protrusions, termed podosomes and their cancer
counterpart’s invadopodia [21, 22]. Podosome-dependent
extracellular matrix remodeling was implicated in cell
migration and invasion during morphogenesis in several
researches [23, 24]. CLASP is necessary for podosome for-
mation. If the CLASP2 is depleted by siRNA, podosome
numbers would be dramatically reduced as compared with
those of cells treated with non-targeted control siRNA [8].
Previous results showed CLASP2 was enriched at the
cortex of basal progenitor keratinocytes. Reductions in the
levels of CLASP2 decreased the localization of the other
protein to cell-cell contacts and altered adherens junctions
dynamics and stability [6]. In our study, ectopic introduc-
tion of CLASP2 resulted in increased growth and aggres-
sive phenotype of bladder cancer cells.
Although we did not study the changes of podosome
or invadopoda in present study, we confirmed the
involvement of CLASP2 in the cellular motility. After
the expression of CLASP2 was up- or down-regulated
by cDNA or shRNA, EMT-related markers including E-
cadherin and Vimentin changed accordingly. Moreover,
wound healing assay indicated that motile potential
could be boosted greatly due to the overexpression of
Fig. 4 ROC curves used to compare the diagnostic potential of tumor grade and those of CLASP2 (a), E-cadherin (b) and Vimentin (c) mRNA levels in
tumor and urine. The greater potential was shown in the combination of CLASP2 and E-cadherin mRNA in urine (d)
Table 3 ROCa curve analysis of CLASP2 and EMT markers for
the discrimination of progression within 2 years
AUCb 95% CIc P
Tumor grade 0.613 0.512–0.708 0.02
CLASP2 mRNA (in tumor) 0.702 0.603–0.788 <0.01
CLASP2 mRNA (in urine) 0.716 0.619–0.801 <0.01
E-cadherin mRNA (in tumor) 0.692 0.593–0.780 <0.01
E-cadherin mRNA (in urine) 0.710 0.612–0.795 <0.01
Vimentin mRNA (in tumor) 0.657 0.544–0.768 0.01
Vimentin mRNA (in urine) 0.687 0.580–0.792 <0.01
Combination of CLASP2 and
E-cadherin mRNA (in urine)
0.763 0.662–0.864 <0.01
aROC: receiver operating characteristic
bAUC: area under the curve
cConfidence interval of AUC
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CLASP2. Cell migration is essential for development,
tissue remodeling and wound healing, and requires
coordination of intracellular signaling and cytoskeleton
dynamics to generate traction forces. CLASP can
promote the stability of peripheral microtubules [25].
However, the study of Nakaya et al. [11] seemed to be
inconsistent with ours. They reported that CLASP2 is
involved in gastrulation, one of the best-known examples
of EMT. The function of CLASP2 was to maintain base-
ment membrane integrity through their microtubules-
binding ability during EMT under this circumstance
[11]. Knockdown of CLASP leaded to premature base-
ment membrane breakdown in lateral epiblast cells and
initiated gastrulation EMT. We thought the reason of
different roles of CLASP2 reported in two studies might
be due to the different cell models (chicken epiblast cells
vs. bladder cancer cells). And we hypothesized that
CLASP2 might play varied roles during the diverse
phases of EMT. During the early EMT, expression of
CLASP2 might need to decrease so the cells could
detach from the basement membrane. Then the expres-
sion would go up with the motile and invasive potential
getting greater. These theories are worthy of further
investigation.
A number of studies have proved the E-cadherin
down-regulation at the transcriptional and protein level
could be used to predict progression and poor prognosis
for the patients with bladder cancer [26–28], which were
consistent with our study. In univariable and multivari-
able analysis, low expressions of E-cadherin in tumor
and urine cells were risk factors for progression within 2
years. However, the significance of soluble E-cadherin in
urine differed from the expression in urine cytology.
Shariat et al. [29] utilized ELISA assay to study the
soluble E-cadherin in the urine of patients with bladder
cancer. The results suggested that higher soluble E-
cadherin was associated with an increased risk of
bladder cancer and could be used as a tool to detect the
recurrence. But the significance of soluble E-cadherin in
bladder cancer progression was not included in their
study. The correlation of E-cadherin between in tumor,
urine cytology and urine itself needs more clarification.
No significance of CLASP2 in bladder cancer or urine
has been reported. Therefore, we could not compare our
findings with others concerning CLASP2. In our study,
univariable and multivariable analysis suggested that
high expressions of CLASP2 in tumor and urine cells
were risk factors for progression within 2 years. These
results suggest that CLASP2 is crucially implicated in
the carcinogenesis and invasion of BC.
Few studies about the roles of Vimentin in bladder
cancer had been published. The role of Vimentin in
predicting progression of bladder cancer is obscure.
Zhao et al. [30] used immunohistochemistry to test the
expression of Vimentin in bladder cancer. They con-
cluded that Vimentin is potential independent indicators
in predicting bladder cancer progression and survival.
But interestingly, Ohsaki et al. [31] found out that all the
urothelial carcinoma cells in voided urine of their study
were negative for Vimentin. The results from this study
might not represent this particular urine cytology feature
of bladder cancer because they only included low-grade
bladder tumor. In our study, expression of Vimentin, as
a mesenchymal marker changed when CLASP2 was up- or
down-regulated in vitro experiments. But the univariable
and multivariable analysis did not suggest any significance
of Vimentin in predicting progression.
Since the results of logistic regression indicated
CLASP2 and E-cadherin mRNA levels in tumor and
urine were risk factors for progression of bladder cancer,
the values of these biomarkers in discriminating the
patients with 2-years progression from those without
were further evaluated by ROC analysis. None of mRNA
levels of individual CLASP2 or the EMT-related markers
in tumor and urine showed better discriminating value
than tumor grade (Fig. 3). But the combination of
CLASP2 and E-cadherin mRNA levels in urine provided
the significant discrimination between patients with
and without 2-years progression compared with the
grade (P = 0.03). To our knowledge, no other studies
focusing on predicting early (2 years) progression
after TURBT had been reported.
This study had some limitations. First, we confirmed
the relationship between CLASP2 and EMT in bladder
cancers, but the results were descriptive. The deeper
molecular mechanisms need much more works and
would be very interesting. Second, number of cases was
relatively small. A larger sample size would ensure
greater degree of accuracy in conclusions.
Conclusion
In conclusion, CLASP2 is involved in the EMT and
progression of bladder urothelial cancer. Simultaneous
urine-based detection of CLASP2 and E-cadherin
mRNA can efficiently discriminate patients with or
without 2-years progression after TURBT.
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